Literature DB >> 14567139

Intrathecal medication delivery.

Richard D Penn1.   

Abstract

This brief review of intrathecal pain medication delivery has emphasized the unusual but useful pharmacology of CSF drug delivery, the new study definitely showing that the method is helpful in cancer pain, and the rare complication of mass formation at the catheter tip. As new medications are developed for intrathecal delivery, this field is likely to expand, especially if a wider range of dorsal horn receptor mechanisms underlying pain processing can be modified. The changes in spinal cord signaling that are induced by chronic pain states are being investigated, and new possibilities for intervention are likely. the availability of a reliable well-understood way of delivering such new therapies by implanted drug pumps will speed the process. Intrathecal morphine for chronic pain has an important role in helping many patients with a wide variety of pain conditions and, as with all pain treatment, is woefully underused.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567139     DOI: 10.1016/s1042-3680(03)00016-0

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  4 in total

1.  Progressive adult spinal deformity following placement of intrathecal opioid pump: a report of four cases.

Authors:  Jared W Daniel; Geoffrey F Haft
Journal:  Iowa Orthop J       Date:  2014

Review 2.  Intrathecal pumps.

Authors:  Shawn Belverud; Alon Mogilner; Michael Schulder
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

3.  Subarachnoid hemorrhage and the distribution of drugs delivered into the cerebrospinal fluid. Laboratory investigation.

Authors:  Ryszard M Pluta; John A Butman; Bawarjan Schatlo; Dennis L Johnson; Edward H Oldfield
Journal:  J Neurosurg       Date:  2009-11       Impact factor: 5.115

4.  Antisense-based therapy for the treatment of spinal muscular atrophy.

Authors:  Frank Rigo; Yimin Hua; Adrian R Krainer; C Frank Bennett
Journal:  J Cell Biol       Date:  2012-10-01       Impact factor: 10.539

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.